Status:
RECRUITING
Registry of Asthma Characterization and Recruitment 3 (RACR3)
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Asthma
Eligibility:
All Genders
Brief Summary
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in U...
Detailed Description
Protocol CAUSE-02 RACR3 is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Ch...
Eligibility Criteria
Inclusion
- Participant is either:
- At least 18 years old, willing and able to provide informed consent at the time of enrollment
- Under the age of 18, accompanied by a legal guardian who is willing and able to provide informed consent at the time of enrollment
- Participant has a primary place of residence within the Office of Management and Budget (OMB)-defined Metropolitan Statistical Area (MSA)
Exclusion
- Participant does not speak English or Spanish and/or guardian does not speak English or Spanish
- Participant does not have access to a phone, either personal or public, with regularity that could be used for scheduling and safety follow-up
- Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may affect the quality or interpretation of the data obtained from the study
- Participants who are pregnant or lactating will not be excluded or discontinued from the study, but will not undergo any procedures that are prohibited during pregnancy per the Childhood Asthma in Urban Settings 02 (CAUSE-02) Registry for Asthma Characterization and Recruitment 3 (RACR3) Manual of Procedures (MOP)(e.g., allergen skin testing, spirometry) during the pregnancy.
- Potential participants may be reassessed as outlined in the Protocol CAUSE-02 MOP.
Key Trial Info
Start Date :
April 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT05272241
Start Date
April 15 2022
End Date
May 1 2028
Last Update
June 22 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Colorado: Allergy Program
Aurora, Colorado, United States, 80045
2
Children's National Medical Center: Inner City Asthma Consortium (ICAC) Clinical Research Site
Washington D.C., District of Columbia, United States, 20010
3
Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology
Chicago, Illinois, United States, 60611
4
Boston Children's Hospital: Department of Immunology
Boston, Massachusetts, United States, 02215